The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer

  • Authors:
    • Nadim Bou Zgheib
    • Yin Xiong
    • Douglas C. Marchion
    • Elona Bicaku
    • Hye Sook Chon
    • Xiaomang Ba Stickles
    • Entidhar Al Sawah
    • Patricia L. Judson
    • Ardeshir Hakam
    • Jesus Gonzalez-Bosquet
    • Robert M. Wenham
    • Sachin M. Apte
    • Christopher L. Cubitt
    • Dung Tsa Chen
    • Johnathan M. Lancaster
  • View Affiliations

  • Published online on: April 26, 2012     https://doi.org/10.3892/ijo.2012.1451
  • Pages: 179-188
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Ovarian cancer (OVCA) is the most lethal gynecological malignancy. The high mortality rate associated with this disease is due in large part to the development of resistance to chemotherapy; however, the biological basis of this remains unclear. Gemcitabine is frequently used for the treatment of patients with platinum-resistant OVCA. We report molecular signaling pathways associated with OVCA response to gemcitabine. Forty-one OVCA cell lines were subjected to gene expression analysis; in parallel, IC50 values for gemcitabine were quantified using CellTiter-Blue viability assays. Pearson's correlation coefficients were calculated for gene expression and gemcitabine IC50 values. The genes associated with gemcitabine sensitivity were subjected to pathway analysis. For the identified pathways, principal component analysis was used to derive pathway signatures and corresponding scores, which represent overall measures of pathway expression. Expression levels of the identified pathways were then evaluated in a series of clinico-genomic datasets from 142 patients with stage III/IV serous OVCA. We found that in vitro gemcitabine sensitivity was associated with expression of 131 genes (p<0.001). These genes include significant representation of three molecular signaling pathways (p<0.02): O-glycan biosynthesis, Role of Nek in cell cycle regulation and Antiviral actions of Interferons. In an external clinico-genomic OVCA dataset (n=142), expression of the O-glycan pathway was associated with overall survival, independent of surgical cytoreductive status, grade and age (p<0.001). Expression levels of Role of Nek in cell cycle regulation and Antiviral actions of Interferons were not associated with survival (p=0.31 and p=0.54, respectively). Collectively, expression of the O-glycan biosynthesis pathway, which modifies protein function via post-translational carbohydrate binding, is independently associated with overall survival from OVCA. Our findings shed light on the molecular basis of OVCA responsiveness to gemcitabine and also identify a signaling pathway that may influence patient survival.

Related Articles

Journal Cover

July 2012
Volume 41 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Bou Zgheib N, Xiong Y, Marchion DC, Bicaku E, Chon HS, Stickles XB, Sawah EA, Judson PL, Hakam A, Gonzalez-Bosquet J, Gonzalez-Bosquet J, et al: The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer. Int J Oncol 41: 179-188, 2012.
APA
Bou Zgheib, N., Xiong, Y., Marchion, D.C., Bicaku, E., Chon, H.S., Stickles, X.B. ... Lancaster, J.M. (2012). The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer. International Journal of Oncology, 41, 179-188. https://doi.org/10.3892/ijo.2012.1451
MLA
Bou Zgheib, N., Xiong, Y., Marchion, D. C., Bicaku, E., Chon, H. S., Stickles, X. B., Sawah, E. A., Judson, P. L., Hakam, A., Gonzalez-Bosquet, J., Wenham, R. M., Apte, S. M., Cubitt, C. L., Chen, D. T., Lancaster, J. M."The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer". International Journal of Oncology 41.1 (2012): 179-188.
Chicago
Bou Zgheib, N., Xiong, Y., Marchion, D. C., Bicaku, E., Chon, H. S., Stickles, X. B., Sawah, E. A., Judson, P. L., Hakam, A., Gonzalez-Bosquet, J., Wenham, R. M., Apte, S. M., Cubitt, C. L., Chen, D. T., Lancaster, J. M."The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer". International Journal of Oncology 41, no. 1 (2012): 179-188. https://doi.org/10.3892/ijo.2012.1451